secwatch.observer — SEC 8-K summary
======================================

Issuer:     Moleculin Biotech, Inc. (MBRX)
CIK:        0001659617
Form:       8-K
Filed at:   2025-12-08T23:59:59+00:00
Accession:  0001437749-25-037084
Event type: other_material
Sentiment:  positive
Materiality: 0.40
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Moleculin partners with CIC biomaGUNE for preclinical Annamycin glioblastoma study
--------------------------------------------------------------------------------

- Agreement supplies Annamycin for investigator-initiated preclinical research at CIC biomaGUNE, Spain.
- Studies compare intra-arterial L-Annamycin and Free-Annamycin vs Doxil and free doxorubicin in mouse GBM models.
- Principal investigator Jesús Ruiz-Cabello to lead the evaluation of tumor progression.
- Annamycin holds FDA Fast Track and Orphan Drug Designation for AML and STS lung metastases.
- GBM is the most common malignant brain tumor with median survival of 15 months.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1659617/000143774925037084/0001437749-25-037084-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1659617/000143774925037084/mbrx20251205_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-037084

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer